GB-5267 - IV only

Phase 1Biologic

RRoswell Park Cancer Institute

GB-5267 - IV only is one of 44 biologic programs targeting Ovarian Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerActive, not recruiting

Platinum-Resistant Ovarian CancerRecruiting

Ovarian CancerPhase 1

Active, not recruiting

Platinum-Resistant Ovarian CancerPhase 1

Recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

BBio-Thera Solutions

Phase 3

83 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

22 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

21 4

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 5

Nolvadex

AstraZeneca

Phase 3

2 6

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

2 7

Masitinib

AAB Science

Phase 3

1 8

Karenitecin

BBioNumerik Pharmaceuticals, Inc.

Phase 3

1 9

Azenosertib

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

2 10

Batiraxcept

AAravive, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 1Recruiting

Platinum-Resistant Ovarian Cancer

NCT07489287

Clinical

Trials by Indication[1]

Platinum-resistant Ovarian Cancer1 trial

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer

Recruiting·RRoswell Park Cancer Institute·Phase 1·NCT07489287·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GB-5267 - IV only. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GB-5267 - IV only compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GB-5267 - IV only. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roswell Park Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: RRoswell Park Cancer Institute

GB-5267 - IV only

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Platinum-resistant Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News